Stone, Roslynn E.
Liu, Siyu
Levy, Alexander M.
Kashani, Nicole
Louie, Stan G.
Rodgers, Kathleen E.
Kelland, Eve E.
Lund, Brett T. http://orcid.org/0000-0002-4167-2271
Funding for this research was provided by:
U.S. Department of Defense (MS 130053)
Article History
Received: 25 March 2019
Accepted: 12 November 2019
First Online: 11 December 2019
Compliance with Ethical Standards
: This animal study was performed in accordance with ethical and humane standards set forth by the National Institutes of Health, and with the approval of University of Southern California’s Institutional Animal Care and Use Committee.
: All of the authors of this manuscript declare no conflict of interest. Dr. Lund has however received investigator-initiated funding from Teva Pharmaceutical Industries, Novartis Pharmaceuticals Corporation and Sanofi-Genzyme for projects unrelated to this work. Dr. Lund has also received honoraria from Teva for projects unrelated to this work. Dr. Kelland has received investigator-initiated funding from Teva Pharmaceutical Industries and Novartis Pharmaceuticals Corporation for projects unrelated to this work. Drs. Rodgers, Stone, Liu, Levy, Kashani and Louie have no industry related conflicts regarding research in multiple sclerosis. Drs. Lund, Kelland, Louie and Rodgers are inventors of U.S. Patent No. 9,623,084.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in these studies involving animals were in accordance with ethical and humane standards set forth by the National Institutes of Health, and with the approval of University of Southern California’s Institutional Animal Care and Use Committee. This article does not contain any studies with human participants performed by any of the authors.